



## Jazz Pharmaceuticals to Report 2023 First Quarter Financial Results on May 10, 2023

April 26, 2023

DUBLIN, April 26, 2023 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it will report its 2023 first quarter financial results on Wednesday, May 10, 2023, after the close of the U.S. financial markets. Company management will host a live audio webcast at 4:30 p.m. ET / 9:30 p.m. IST to discuss 2023 first quarter financial results and provide a business and financial update.

Interested parties may register for the call in advance [here](#) or via the Investors section of the Jazz Pharmaceuticals website at [www.jazzpharmaceuticals.com](http://www.jazzpharmaceuticals.com). To ensure a timely connection, it is recommended that participants register at least 15 minutes prior to the scheduled webcast.

A replay of the webcast will be available via the Investors section of the Jazz Pharmaceuticals website at [www.jazzpharmaceuticals.com](http://www.jazzpharmaceuticals.com).

### **About Jazz Pharmaceuticals**

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) is a global biopharmaceutical company whose purpose is to innovate to transform the lives of patients and their families. We are dedicated to developing life-changing medicines for people with serious diseases – often with limited or no therapeutic options. We have a diverse portfolio of marketed medicines and novel product candidates, from early- to late-stage development, in neuroscience and oncology. Within these therapeutic areas, we are identifying new options for patients by actively exploring small molecules and biologics, and through innovative delivery technologies and cannabinoid science. Jazz is headquartered in Dublin, Ireland and has employees around the globe, serving patients in nearly 75 countries. Please visit [www.jazzpharmaceuticals.com](http://www.jazzpharmaceuticals.com) for more information.

### **Investors:**

Andrea N. Flynn, Ph.D.  
Vice President, Head, Investor Relations  
Jazz Pharmaceuticals plc  
[InvestorInfo@jazzpharma.com](mailto:InvestorInfo@jazzpharma.com)  
Ireland +353 1 634 3211  
U.S. +1 650 496 2717

### **Media Contact:**

Kristin Bhavnani  
Head of Global Corporate Communications  
Jazz Pharmaceuticals plc  
[CorporateAffairsMediaInfo@jazzpharma.com](mailto:CorporateAffairsMediaInfo@jazzpharma.com)  
Ireland +353 1 637 2141  
U.S. +1 215 867 4948



 View original content to download multimedia: <https://www.prnewswire.com/news-releases/jazz-pharmaceuticals-to-report-2023-first-quarter-financial-results-on-may-10-2023-301807430.html>

SOURCE Jazz Pharmaceuticals plc